ArticleCalcified tissue international2026
Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fracture risk assessment in early-stage autosomal dominant polycystic kidney disease: a cross-sectional study using FRAXBMC nephrology · 2026Article
- The Important Role of Polycystin in the Skeletal System.Calcified tissue international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a systemic ciliary disorder, yet the impact on bone health remains insufficiently defined. Given the expression of polycystins in osteocytes, osteoclasts and extracellular matrix, a disease-specific bone phenotype has been hypothesized. This study aimed to comprehensively characterize the bone phenotype in ADPKD across stages of chronic kidney disease (CKD) and Mayo Imaging Classification (MIC). In this cross-sectional study, 81 patients with ADPKD, 15 with CKD of other etiologies, and 21 healthy individuals were included. Bone phenotype was assessed across four domains: bone metabolism biomarkers, bone turnover biomarkers, bone mass/microarchitecture (dual-energy X-ray absorptiometry with trabecular scoring (TBS)) and bone material strength (microindentation, BMSi). Z-score-based heat-maps were used to visualize stage-specific alterations, and multivariable regression analysis was applied to estimate model parameters. ADPKD patients consistently showed lower bone turnover, particularly PINP and in CKD G1-2 also BALP, while BMSi, BMD and TBS did not differ from healthy individuals. Across CKD stages, mineral abnormalities reflected the effect of declining eGFR, whereas stratification by MIC revealed less distinct patterns, indicating that the bone phenotype may be more closely linked to CKD progression than cystic burden in later CKD stages. This first comprehensive analysis of the ADPKD bone phenotype reveals mineral disturbances, reduced bone turnover, and preserved bone mass and microarchitecture in early ADPKD. Bone alterations followed kidney function rather than MIC stage. Impact microindentation, BMSi, did not reveal any distinctive pattern in ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.